Top Healthcare Stocks to Watch: Axsome Therapeutics, Rocket Pharmaceuticals, and Humana Receive Bullish Sentiments from Analysts

Analysts are bullish on top healthcare stocks Axsome Therapeutics (AXSM), Rocket Pharmaceuticals (RCKT), and Humana (HUM) with strong Buy ratings and price targets. Mizuho Securities analyst Graig Suvannavejh reiterated a Buy rating on AXSM with a $200.00 price target, while Whitney Ijem from Canaccord Genuity maintained a Buy rating on RCKT with a $10.00 price target. RBC Capital analyst Daniel Perlin maintained a Buy rating on HUM with a $322.00 price target.

Analysts are expressing optimism about several top healthcare stocks, with strong Buy ratings and price targets. Mizuho Securities analyst Graig Suvannavejh reiterated a Buy rating on Axsome Therapeutics (AXSM) with a $200.00 price target [2]. Whitney Ijem from Canaccord Genuity maintained a Buy rating on Rocket Pharmaceuticals (RCKT) with a $10.00 price target [1]. RBC Capital analyst Daniel Perlin maintained a Buy rating on Humana (HUM) with a $322.00 price target [2].

Axsome Therapeutics (AXSM)
Mizuho Securities analyst Graig Suvannavejh reiterated a Buy rating on AXSM with a $200.00 price target. The analyst cited the company's promising pipeline and recent positive clinical trial data for its lead asset, AXS-05. AXS-05 is a novel therapy for the treatment of Alzheimer's disease, and its successful Phase 2b results have fueled investor confidence.

Rocket Pharmaceuticals (RCKT)
Whitney Ijem from Canaccord Genuity maintained a Buy rating on RCKT with a $10.00 price target. The analyst highlighted the company's pivotal Phase 2 trial for RP-A501, which resumed after the FDA lifted a three-month clinical hold. The trial's success hinges on secondary endpoints and patient safety, with potential re-rating to $5–$7 if Phase 2 data meets expectations [1].

Humana (HUM)
RBC Capital analyst Daniel Perlin maintained a Buy rating on HUM with a $322.00 price target. The analyst raised the price target following Humana's impressive second-quarter 2025 results, which exceeded expectations with earnings per share of $6.27 and revenue of $32.39 billion. RBC expressed encouragement about management's optimistic tone regarding strong Net Promoter Scores (NPS) and member efficacy, suggesting a better-than-expected position for Humana [2].

These analyst ratings reflect a positive outlook on the healthcare sector, with a focus on the companies' clinical progress, financial performance, and market positioning. Investors should consider these ratings alongside their own risk tolerance and investment objectives.

References:
[1] https://www.ainvest.com/news/rocket-pharmaceuticals-rp-a501-trial-resumes-catalyst-rating-2508/
[2] https://www.investing.com/news/analyst-ratings/rbc-capital-raises-humana-stock-price-target-to-322-on-stars-bonus-recovery-93CH-4204059